1. Apoptosis
  2. Caspase

VX-765 (Synonyms: Belnacasan)

Cat. No.: HY-13205 Purity: 99.99%
Handling Instructions

VX-765 is an orally active IL-converting enzyme/caspase-1 inhibitor, inhibits IL-1β release with similar potency in PBMCs from FCAS (IC50=0.99±0.29 μM) and control (IC50=1.1±0.61 μM) subjects.

For research use only. We do not sell to patients.

VX-765 Chemical Structure

VX-765 Chemical Structure

CAS No. : 273404-37-8

Size Price Stock Quantity
Free Sample (0.5-1 mg)   Apply now  
10 mM * 1 mL in DMSO USD 94 In-stock
Estimated Time of Arrival: December 31
5 mg USD 84 In-stock
Estimated Time of Arrival: December 31
10 mg USD 119 In-stock
Estimated Time of Arrival: December 31
50 mg USD 300 In-stock
Estimated Time of Arrival: December 31
100 mg USD 540 In-stock
Estimated Time of Arrival: December 31
200 mg   Get quote  
500 mg   Get quote  

* Please select Quantity before adding items.

Customer Review

    VX-765 purchased from MCE. Usage Cited in: Brain Behav Immun. 2016 Aug;56:175-86.

    The effects of NLRP3 inflammasome inhibitor VX-765 on NF-κB and CD11b levels in Sham and OVX groups. Sham operation or bilateral ovariectomy is performed and then the mice are subcutaneously administrated with the chemicals as indicated for four weeks. (A) p-p65 protein level with representative protein bands presented on top of histogram; (B) CD11b protein level with representative protein bands presented on top of histogram.

    VX-765 purchased from MCE. Usage Cited in: Brain Behav Immun. 2017 Oct;65:99-110.

    VX765 treatment successfully inhibits the caspase 1 activity and reduces nuclear TDP-43 and cleaved caspase-3 protein levels in the hippocampus of BDE-47-treated mice.

    VX-765 purchased from MCE. Usage Cited in: Toxicology. 2018 Sep 8;410:26-40.

    HUVECs are primed with 1 μg/mL LPS for 2 h, and then pretreated with or without 5 μM VX-765 for 1 h; following by treatment with Acrolein (50 μM) for 24 h. Western blot is performed to determine the expression of cleaved caspase-1, IL-1β and IL-18.
    • Biological Activity

    • Protocol

    • Technical Information

    • Purity & Documentation

    • References

    Description

    VX-765 is an orally active IL-converting enzyme/caspase-1 inhibitor, inhibits IL-1β release with similar potency in PBMCs from FCAS (IC50=0.99±0.29 μM) and control (IC50=1.1±0.61 μM) subjects.

    IC50 & Target[1]

    Caspase-1

     

    In Vitro

    VX-765 inhibits the release of LPS-induced IL-1β and IL-18 by human PBMCs with an IC50 of ~0.7 μM and reduces inflammatory response in murine models of inflammatory disease[1]. VX-765 is a potent, specific inhibitor of the caspase-1 subfamily[2].

    In Vivo

    VX-765 doses 50, 100, and 200 mg/kg significantly (p<0.05) reduces serum IL-1β levels by as much as 60%, whereas 25 mg/kg has a smaller effect (~35% inhibition) that is not statistically significant. It is noteworthy that the effect of VX-765 on the release of IL-1β induced by LPS reached a plateau at 100 mg/kg. VX-765 (25, 50, and 100 mg/kg × 2) significantly reduces ear edema. VX-765 also dose-dependently reduces the concentrations of cytokines, chemokines, and inflammatory mediators in the ear biopsy samples[2]. VX-765 at doses of 25, 50, and 200 mg/kg significantly delays the time to seizure onset by 1.5- to twofold (p<0.01), reduces the number of seizures by 40% (p<0.01) and the total time spent in EEG seizure activity by 30 to 50% (p<0.01)[3].

    Clinical Trial
    Solvent & Solubility
    In Vitro: 

    DMSO : ≥ 27 mg/mL (53.05 mM)

    *"≥" means soluble, but saturation unknown.

    Preparing
    Stock Solutions
    Concentration Solvent Mass 1 mg 5 mg 10 mg
    1 mM 1.9646 mL 9.8232 mL 19.6464 mL
    5 mM 0.3929 mL 1.9646 mL 3.9293 mL
    10 mM 0.1965 mL 0.9823 mL 1.9646 mL
    *Please refer to the solubility information to select the appropriate solvent.
    In Vivo:
    • 1.

      Add each solvent one by one:  10% DMSO    90% corn oil

      Solubility: ≥ 2.08 mg/mL (4.09 mM); Clear solution

    • 2.

      Add each solvent one by one:  10% DMSO    40% PEG300    5% Tween-80    45% saline

      Solubility: ≥ 2.08 mg/mL (4.09 mM); Clear solution

    • 3.

      Add each solvent one by one:  10% DMSO    90% (20% SBE-β-CD in saline)

      Solubility: ≥ 2.08 mg/mL (4.09 mM); Clear solution

    References
    Kinase Assay
    [2]

    Enzyme inhibition is assayed by tracking of the rate of hydrolysis of an appropriate substrate labeled with either p-nitroaniline or aminomethyl coumarin (AMC) as follows: ICE/caspase-1, suc-YVAD-p-nitroanilide; caspase-4, Ac-WEHD-AMC; caspase-6, Ac-VEID-AMC; caspase-3, -7, -8, and -9, Ac-DEVD-AMC; and granzyme B, Ac-IEPD-AMC. Enzymes and substrates are incubated in a reaction buffer [10 mM Tris, pH 7.5, 0.1% (w/v) CHAPS, 1 mM dithiothreitol, and 5% (v/v) DMSO] for 10 min at 37°C. Glycerol is added to the buffer at 8% (v/v) for caspase-3, -6, and -9 and granzyme B to improve stability of enzymes. The rate of substrate hydrolysis is monitored using a fluorometer. Assays for cathepsin B and trypsin are performed[2].

    MCE has not independently confirmed the accuracy of these methods. They are for reference only.

    Cell Assay
    [1]

    A total of 2×105 cells/well (100 μL cell suspension) is distributed in triplicate in flat-bottom 96-well plates. Either 50 μL of VX-765 (40 μM in RPMI 1640 complete medium containing 0.2% DMSO) or vehicle control is added to appropriate wells. Following a 30-min incubation at 37°C, 50 μL of LPS diluted in RPMI 1640 complete medium is added at final concentrations varying from 0.001 to 10 ng/mL. Cells are returned to a 37°C incubator. At 4 h after LPS addition, 75 μL of supernatant is removed from wells, cleared by centrifugation for 5 min at 1500 rpm, and stored at 4°C until assayed. Cells are returned to a 37°C incubator until 24 h after LPS addition, at which time 100 μL of supernatant is removed, cleared by centrifugation, and stored at 4°C. Supernatants are tested using ELISA kits for IL-1β, IL-6, IL-18, and IL-1α[1].

    MCE has not independently confirmed the accuracy of these methods. They are for reference only.

    Animal Administration
    [2][3]

    Mice[2]
    Single doses of VX-765 (10, 21, 43, and 84 mg/kg) in vehicle (25% Cremophor EL in water) are administered via oral gavage. Blood samples (approximately 0.25-0.3 mL) are collected before dose administration and 0.167, 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, and 24 h after dosing via the retroorbital sinus and processed for plasma. A high-performance liquid chromatography/mass spectrometry methodology is used to determine the concentration of VX-765 and VRT-043198 in plasma samples. Noncompartmental analysis is carried out using WinNonlin Pro, version 4.0.1.
    Rats[3]
    Male Sprague-Dawley rats (250-280 g) are used. VX-765 (25, 50, 200 mg/kg) is dissolved in 20% Cremophor and injected ip in rats once a day for 3 consecutive days. On the fourth day, rats received VX-765, 45 min and 10 min before intrahippocampal injection of kainic acid. Respective controls are similarly injected with vehicle before kainic acid.

    MCE has not independently confirmed the accuracy of these methods. They are for reference only.

    References
    Molecular Weight

    509.00

    Formula

    C₂₄H₃₃ClN₄O₆

    CAS No.

    273404-37-8

    SMILES

    ClC1=C(N)C=CC(C(N[[email protected]@H](C(C)(C)C)C(N2[[email protected]](C(N[[email protected]]3CC(O[[email protected]]3OCC)=O)=O)CCC2)=O)=O)=C1

    Storage
    Powder -20°C 3 years
      4°C 2 years
    In solvent -80°C 6 months
      -20°C 1 month
    Shipping

    Room temperature in continental US; may vary elsewhere

    Purity: 99.99%

    • Molarity Calculator

    • Dilution Calculator

    The molarity calculator equation

    Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

    Mass   Concentration   Volume   Molecular Weight *
    = × ×

    The dilution calculator equation

    Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

    This equation is commonly abbreviated as: C1V1 = C2V2

    Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
    × = ×
    C1   V1   C2   V2

    Inquiry Online

    Your information is safe with us. * Required Fields.

    Product name

     

    Salutation

    Applicant name *

     

    Email address *

    Phone number *

     

    Organization name *

    Country or Region *

     

    Requested quantity *

    Remarks

    Bulk Inquiry

    Inquiry Information

    Product Name:
    VX-765
    Cat. No.:
    HY-13205
    Quantity:

    VX-765

    Cat. No.: HY-13205